WEKO3
アイテム
Ethics and Regulation of Precision Medicine in Nuclear Medicine:
https://repo.qst.go.jp/records/66008
https://repo.qst.go.jp/records/660087cc32ff8-75ee-47a2-a79f-50aee3750755
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2016-11-07 | |||||
| タイトル | ||||||
| タイトル | Ethics and Regulation of Precision Medicine in Nuclear Medicine: | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
栗原, 千絵子
× 栗原, 千絵子× 栗原 千絵子 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Background: International collaborative clinical trial network has been more and more facilitated aiming at global regulatory approval of new medical technologies. Especially in the era of “precision medicine”, more precise characterization and classification of therapeutic target population has become to be required. In such situation, PET (positron emission tomography) imaging technology plays key role from the stage of exploratory phase to approval process of new drug development. Hence, clinical trial network along with standardization and validation of PET drug manufacturing and PET imaging site are prerequisite for successful development. Many of Western global companies and academic institutes have developed clinical trial network utilizing PET imaging. In order to facilitate precision medicine utilizing PET imaging more in Asian regions and to expand it aiming at global health, it is necessary to develop Asian-oriented clinical trial network utilizing PET imaging, in ethical and regulatory compliant manner. Methods: Narrative, non-systematic review of literatures, based on experience of our international collaborations with Western and Asian PET communities. Results: Our findings on importance of facilitating Asian-initiated clinical trial network are: (1) to help more efficient participation in Western-initiated international clinical trials in terms of a) promoting standardization of imaging methodology/procedures and PET drug manufacturing; and b) considering characteristics of subgroups of Asian populations for “precision medicine”; (2) to contribute to development of medical technologies for diseases more prevalent in Asian region; (3) to contribute to expanding Asian academic-initiated innovation for global health. Conclusions: Asian-initiated clinical trial network using PET imaging is critically important for promoting “global health” and “precision medicine”, not only for Asian but also wider population in the world. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 第56回日本核医学会学術総会 ARCCNM/ASNMシンポジウムでの講演 | |||||
| 発表年月日 | ||||||
| 日付 | 2016-11-04 | |||||
| 日付タイプ | Issued | |||||
